Filing Details

Accession Number:
0001209191-16-091089
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2016-01-12 19:00:16
Reporting Period:
2015-12-31
Filing Date:
2016-01-12
Accepted Time:
2016-01-12 19:00:16
Original Submission Date:
2016-01-05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1346830 Cara Therapeutics Inc. CARA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1597359 Dean Slagel C/O Esperante Nv,
Siriusdreef 22
Hoofddorp P7 2132 WT
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2015-12-31 12,776 $17.00 1,345,562 No 4 S Indirect By Esperante Holding NV
Common Stock Disposition 2016-01-05 31,224 $17.01 1,314,338 No 4 S Indirect By Esperante Holding NV
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Esperante Holding NV
No 4 S Indirect By Esperante Holding NV
Footnotes
  1. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Esperante Holding NV on December 17, 2015 (See Footnote 3 herein).
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 - $17.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. These shares are owned by Esperante Holding NV. The Reporting Person is a director of the Issuer and the Managing Director of Esperante BV, a wholly-owned subsidiary of Esperante Holding NV. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 - $17.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.